Zacks Small Cap Analysis – MSCLF: On Observe to Provoke Part 1 First-in-Human Trials of SAT-3247 in mid-2024… – Nexus Vista

By David Bautz, PhD



Enterprise Replace

First-in-Human Trial of SAT-3247 to Provoke in Mid-2024

Satellos Bioscience Inc. (OTC:MSCLF) is a growing biopharmaceutical firm targeted on muscle degeneration. Its lead asset, SAT-3247, is being developed as a therapy for Duchenne Muscular Dystrophy (DMD), which is the commonest deadly genetic dysfunction recognized in childhood. The corporate is at present ending the work essential to file for regulatory approval to provoke a Part 1a medical trial of SAT-3247 in wholesome volunteers. Most not too long ago, the corporate has engaged a contract analysis group (CRO) to design and implement the deliberate Part 1a trial. As well as, the required GLP toxicology research are underway, bulk portions of the drug have been produced below GMP circumstances, and tablets of SAT-3247 have been formulated. We anticipate the Part 1a trial initiating in mid-2024 with the trial anticipated to be accomplished by the tip of 2024.

As well as, Satellos introduced it is going to be conducting a Part 1b medical trial in wholesome human volunteers for SAT-3247. This trial is designed to guage the pharmacodynamic (PD) properties of the drug and, if profitable, might present preliminary proof-of-concept proof for SAT-3247’s mechanism of motion. Importantly, this trial won’t delay the deliberate initiation of a Part 1b/2a trial in Duchenne sufferers in 2025.

Monetary Replace

On Might 14, 2024, Satellos introduced monetary outcomes for the primary quarter of 2024. Internet loss for the primary quarter of 2024 was CAD$6.9 million, or CAD($0.06), in comparison with CAD$1.7 million, or CAD($0.04), for the primary quarter of 2023. The rise in web loss was primarily as a result of elevated R&D bills related to SAT-3247 in addition to elevated G&A bills as a result of elevated personnel {and professional} charges. R&D bills for the primary quarter of 2024 had been CAD$5.9 million in comparison with CAD$0.9 million for the primary quarter of 2023. The rise was as a result of larger wage and administration charges, elevated preclinical and pre-IND-enabling bills, and elevated CMC bills. G&A bills within the first quarter of 2024 had been CAD$2.3 million in comparison with CAD$0.7 million for the primary quarter of 2023. The rise was primarily as a result of larger wage and administration charges, larger skilled charges, and elevated non-cash stock-based compensation.

As of March 31, 2024, Satellos had roughly CAD$33.2 million in money, money equivalents, and quick time period investments. As of Might 14, 2024, Satellos had roughly 112.8 million shares excellent and, when factoring in choices and warrants, a completely diluted share depend of 179.2 million.


Satellos continues to current very encouraging preclinical knowledge for SAT-3247 and the latest outcomes present proof that the compound might have extra applicability in different muscle degenerative ailments and muscle harm. We proceed to anticipate a first-in-human medical trial for SAT-3247 in mid-2024. With no modifications to our mannequin our valuation stays at $1.00 per share.

SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to obtain our articles and studies emailed on to you every morning. Please go to our web site for extra data on Zacks SCR. 

DISCLOSURE: Zacks SCR has acquired compensation from the issuer instantly, from an funding supervisor, or from an investor relations consulting agency, engaged by the issuer, for offering analysis protection for a interval of at least one yr. Analysis articles, as seen right here, are a part of the service Zacks SCR gives and Zacks SCR receives quarterly funds totaling a most charge of as much as $40,000 yearly for these companies supplied to or relating to the issuer. Full Disclaimer HERE.

Add a Comment

Your email address will not be published. Required fields are marked *